GlassScriptPhysician profile
Manisha Chandalia
NPI 1750347217
$385,884.72
in general payments reported to CMS, 2019-2025
56 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128K · 2020: $48K · 2021: $40K · 2022: $42K · 2023: $59K · 2024: $48K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $108K · Consulting Fee: $8,388 · Food and Beverage: $6,150 · Travel and Lodging: $4,905 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $108,129.50 |
| Consulting Fee | $8,387.50 |
| Food and Beverage | $6,150.17 |
| Travel and Lodging | $4,905.28 |
| Education | $105.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $120,937.76 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114,549.60 | 2019-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $74,723.92 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $50,783.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $11,531.52 | 2019-2025 | Evenity, Prolia, Repatha |
| Regeneron Pharmaceuticals, INC. | $3,789.90 | 2021 | |
| Merck Sharp & Dohme LLC | $2,878.99 | 2019-2021 | |
| Mannkind Corporation | $765.07 | 2019-2023 | Afrezza |
| Insulet Corporation | $646.09 | 2019-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $558.12 | 2021-2025 | |
| Amarin Pharma, INC. | $461.37 | 2019-2022 | |
| Radius Health, INC. | $377.33 | 2020-2025 | Tymlos |
| Beta Bionics, INC. | $295.46 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Esperion Therapeutics, INC. | $287.58 | 2020-2023 | Nexletol |
| Madrigal Pharmaceuticals | $286.28 | 2025 | Rezdiffra |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $276.56 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $229.19 | 2022-2025 | |
| Medtronic Minimed, INC. | $203.71 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $203.44 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $146.11 | 2019-2025 | Dexcom G6 Transmitter |
| Inari Medical, INC. | $140.38 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Antares Pharma, INC. | $136.30 | 2020-2024 | Xyosted, Tlando, Nocdurna |
| Allergan, INC. | $124.99 | 2019 | |
| Xeris Pharmaceuticals, INC. | $124.34 | 2021-2024 | Gvoke Hypopen, Recorlev |
| Kyowa Kirin, INC. | $119.36 | 2025 | |
| Corcept Therapeutics | $107.94 | 2019-2024 | Korlym |
| Ibsa Pharma INC. | $103.44 | 2019-2025 | Tirosint, Licart, Tirosint |
| Astellas Pharma US INC | $85.54 | 2024-2025 | Veozah |
| Horizon Therapeutics Plc | $82.45 | 2022-2023 | Tepezza |
| Abbvie INC. | $80.57 | 2021-2025 | Synthroid |
| Medtronic, INC. | $68.25 | 2021-2025 | Inpen Smart Insulin Delivery System, Intellis Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.29 | 2019-2022 | |
| Acerus Pharmaceuticals Corporation | $63.69 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $52.26 | 2025 | Unithroid |
| Halozyme INC | $51.33 | 2023 | |
| Tolmar, INC. | $47.64 | 2024-2025 | Jatenzo |
| Senseonics, Incorporated | $44.00 | 2019 | |
| Cequr Corporation | $38.98 | 2023-2024 | Cequr Simplicity |
| Pfizer INC. | $38.07 | 2021-2022 | |
| Abbott Laboratories | $37.53 | 2021 | |
| Globus Medical, INC. | $32.59 | 2025 | Senza |
| Companion Medical, INC. | $31.84 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $28.54 | 2022-2024 | Crysvita |
| Sequel Med Tech, LLC | $27.04 | 2025 | Twiist |
| Averitas Pharma INC. | $24.57 | 2025 | Qutenza |
| Glaxosmithkline, LLC. | $23.52 | 2025 | Arexvy, Shingrix |
| Clarus Therapeutics INC. | $23.09 | 2021 | |
| Embecta Corp. | $22.87 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Becton, Dickinson and Company | $22.71 | 2020 | |
| Ascendis Pharma Endocrinology INC | $22.46 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $21.14 | 2021 | |
| Acella Pharmaceuticals, LLC | $18.08 | 2025 | NP Thyroid 60 |
| Recordati_rare_diseases_inc. | $15.04 | 2025 | Isturisa |
| Vivus LLC | $14.60 | 2023 | Pancreaze |
| Intuity Medical INC | $13.54 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manisha Chandalia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.